CTC Clinical Trial Consultants AB
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
At CTC Clinical Trial Consultants AB, investigators are evaluating vaccines and treatments aimed at preventing serious bacterial and fungal infections.
- Pneumococcal disease vaccine V116 safety and immunogenicity in children
- Assessment of serotype‑specific opsonophagocytic activity
- Exploration of novel antimicrobial strategies
The trials seek to improve protection against pneumococcal infection and reduce disease burden in high‑risk populations.
Digestive System Diseases
Studies focus on disorders of the gastrointestinal tract, especially celiac disease, to restore intestinal health.
- Evaluation of amlitelimab for non‑responsive celiac disease
- Investigation of gluten‑induced mucosal changes under adjunctive therapy
- Impact of treatment on nutrient absorption and quality of life
The purpose is to test new biologic agents that can reduce intestinal inflammation and improve patient outcomes.
Immune System Diseases
Research targets immune‑mediated conditions such as atopic dermatitis and alopecia areata.
- Amlitelimab monotherapy versus placebo for moderate‑to‑severe atopic dermatitis
- Upadacitinib dosing strategies for severe alopecia areata in adults and adolescents
- Long‑term safety monitoring of immune‑modulating agents
Goals include reducing skin inflammation, promoting hair regrowth, and establishing safe treatment regimens.
Male Urogenital Diseases
Clinical trials explore innovative solutions for erectile dysfunction.
- LIB‑01 efficacy compared with placebo in improving sexual function
- Comprehensive safety assessment of LIB‑01
- Patient‑reported outcome measures of treatment satisfaction
The studies aim to provide a new therapeutic option that enhances performance and quality of life for men.
Nutritional and Metabolic Diseases
The site conducts trials on metabolic disorders, focusing on type 2 diabetes.
- CagriSema versus semaglutide on HbA1c reduction
- Evaluation of body‑weight changes alongside glycemic control
- Assessment of safety in combination with metformin ± SGLT2 inhibitor
The objective is to identify more effective glucose‑lowering agents that also support weight management.
Skin and Connective Tissue Diseases
Investigations address chronic skin conditions, particularly atopic dermatitis.
- Amlitelimab subcutaneous administration for severe eczema
- Comparison of two dosing regimens and treatment withdrawal effects
- Safety and tolerability profiling over extended periods
The purpose is to expand therapeutic choices for patients who have not responded to existing treatments.
Psychiatry and Psychology – Behavior and Behavior Mechanisms
Research examines addictive behaviors, including nicotine dependence.
- Pharmacokinetic comparison of nicotine pouch (NP) dry 4 mg versus Nicorette® lozenge
- Evaluation of craving reduction and user satisfaction
- Safety monitoring in healthy adult cigarette users
The aim is to develop safer nicotine replacement products that support cessation efforts.
Psychiatry and Psychology – Mental Disorders
Trials focus on major depressive disorder with insomnia symptoms and adjunctive therapies.
- Seltorexant 20 mg added to SSRI/SNRI for acute depressive symptom improvement
- Long‑term efficacy of seltorexant in delaying relapse after stable response
- Safety assessment of combined antidepressant regimen
The objective is to enhance depressive symptom relief and maintain remission in patients with inadequate response to standard antidepressants.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novo Nordisk A/S1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CTC Clinical Trial Consultants AB
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Upadacitinib Efficacy and Safety in Adult and Adolescent Patients with Severe Alopecia Areata: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 1 | Unknown | 2026-08-11 | 2026-08-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.